Trafalgar International (GCAN) Net Income towards Common Stockholders (QoQ) (2017 - 2026)
Trafalgar International (GCAN) Net Income towards Common Stockholders (QoQ) (2017 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 44.05 Bn | 43.08 Bn | - |
| 2 | Teva Pharmaceutical Industries | 43.39 Bn | 39.74 Bn | 2.15 Bn |
| 3 | Zoetis | 31.86 Bn | 30.18 Bn | 1.05 Bn |
| 4 | Takeda Pharmaceutical | 28.78 Bn | 22.99 Bn | 5.10 Bn |
| 5 | United Therapeutics | 22.25 Bn | 19.59 Bn | 683.80 Mn |
| 6 | Viatris | 18.74 Bn | 17.85 Bn | 1.46 Bn |
| 7 | Neurocrine Biosciences | 15.58 Bn | 15.19 Bn | 935.80 Mn |
| 8 | Elanco Animal Health | 11.92 Bn | 11.39 Bn | 798.00 Mn |
| 9 | Dr Reddys Laboratories | 10.16 Bn | 9.99 Bn | - |
| 10 | Trafalgar International | 236,233.75 | 236,233.75 | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -109.88% |
| Dec 31, 2025 | 1,035.64% |
| Sep 30, 2025 | 90.76% |
| Jun 30, 2025 | -277.60% |
| Mar 31, 2025 | -138.79% |
| Dec 31, 2024 | 6.10% |
| Sep 30, 2024 | -2.78% |
| Jun 30, 2024 | -0.69% |
| Mar 31, 2024 | 4.80% |
| Dec 31, 2023 | 12.29% |
| Sep 30, 2023 | -18.62% |
| Jun 30, 2023 | -4.59% |
| Mar 31, 2023 | 9.14% |
| Dec 31, 2022 | 53.88% |
| Sep 30, 2022 | -64.69% |
| Jun 30, 2022 | 57.74% |
| Mar 31, 2022 | 24.78% |
| Dec 31, 2021 | 22.18% |
| Sep 30, 2021 | -547.46% |
| Jun 30, 2021 | 66.02% |